These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Re-Engineering RNA Molecules into Therapeutic Agents. Egli M; Manoharan M Acc Chem Res; 2019 Apr; 52(4):1036-1047. PubMed ID: 30912917 [TBL] [Abstract][Full Text] [Related]
3. Probing the influence of stereoelectronic effects on the biophysical properties of oligonucleotides: comprehensive analysis of the RNA affinity, nuclease resistance, and crystal structure of ten 2'-O-ribonucleic acid modifications. Egli M; Minasov G; Tereshko V; Pallan PS; Teplova M; Inamati GB; Lesnik EA; Owens SR; Ross BS; Prakash TP; Manoharan M Biochemistry; 2005 Jun; 44(25):9045-57. PubMed ID: 15966728 [TBL] [Abstract][Full Text] [Related]
4. The Medicinal Chemistry of Artificial Nucleic Acids and Therapeutic Oligonucleotides. Bege M; Borbás A Pharmaceuticals (Basel); 2022 Jul; 15(8):. PubMed ID: 35893733 [TBL] [Abstract][Full Text] [Related]
5. Cationic oligonucleotide derivatives and conjugates: A favorable approach for enhanced DNA and RNA targeting oligonucleotides. Danielsen MB; Wengel J Beilstein J Org Chem; 2021; 17():1828-1848. PubMed ID: 34386102 [TBL] [Abstract][Full Text] [Related]
6. Synthesis and Properties of Nucleobase-Sugar Dual Modified Nucleic Acids: 2 Sakurai Y; Yamaguchi T; Yoshida T; Horiba M; Inoue T; Obika S J Org Chem; 2023 Jan; 88(1):154-162. PubMed ID: 36520114 [TBL] [Abstract][Full Text] [Related]
8. Triazole- and Tetrazole-Bridged Nucleic Acids: Synthesis, Duplex Stability, Nuclease Resistance, and in Vitro and in Vivo Antisense Potency. Mitsuoka Y; Yamamoto T; Kugimiya A; Waki R; Wada F; Tahara S; Sawamura M; Noda M; Fujimura Y; Kato Y; Hari Y; Obika S J Org Chem; 2017 Jan; 82(1):12-24. PubMed ID: 27936689 [TBL] [Abstract][Full Text] [Related]
9. Fine tuning of electrostatics around the internucleotidic phosphate through incorporation of modified 2',4'-carbocyclic-LNAs and -ENAs leads to significant modulation of antisense properties. Zhou C; Liu Y; Andaloussi M; Badgujar N; Plashkevych O; Chattopadhyaya J J Org Chem; 2009 Jan; 74(1):118-34. PubMed ID: 19055352 [TBL] [Abstract][Full Text] [Related]
10. An overview of sugar-modified oligonucleotides for antisense therapeutics. Prakash TP Chem Biodivers; 2011 Sep; 8(9):1616-41. PubMed ID: 21922654 [TBL] [Abstract][Full Text] [Related]
11. Insights from crystallographic studies into the structural and pairing properties of nucleic acid analogs and chemically modified DNA and RNA oligonucleotides. Egli M; Pallan PS Annu Rev Biophys Biomol Struct; 2007; 36():281-305. PubMed ID: 17288535 [TBL] [Abstract][Full Text] [Related]
14. DNA Catalysis: The Chemical Repertoire of DNAzymes. Hollenstein M Molecules; 2015 Nov; 20(11):20777-804. PubMed ID: 26610449 [TBL] [Abstract][Full Text] [Related]
15. Novel phosphoramidite building blocks in synthesis and applications toward modified oligonucleotides. Venkatesan N; Kim SJ; Kim BH Curr Med Chem; 2003 Oct; 10(19):1973-91. PubMed ID: 12871099 [TBL] [Abstract][Full Text] [Related]
16. Chemical Synthesis and Biological Application of Modified Oligonucleotides. Glazier DA; Liao J; Roberts BL; Li X; Yang K; Stevens CM; Tang W Bioconjug Chem; 2020 May; 31(5):1213-1233. PubMed ID: 32227878 [TBL] [Abstract][Full Text] [Related]